北京热景生物技术股份有限公司2025 年半年度报告 北京热景生物技术股份有限公司 2025 年半年度报告 1 / 202 北京热景生物技术股份有限公司2025 年半年度报告 重要提示 一、 本公司董事会及董事、高级管理人员保证半年度报告内容的真实性、准确性、完整性，不 存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 二、 重大风险提示 报告期内，不存在对公司产生实质性重大不利影响的风险因素。公司已在本报告中详细描述 了公司可能面对的风险，具体内容详见本年度报告"第三节经营情况讨论与分析"之"五、风险 因素" 。 三、 公司全体董事出席董事会会议。 公司代码：688068 公司简称：热景生物 四、 本半年度报告未经审计。 五、 公司负责人林长青、主管会计工作负责人石永沾及会计机构负责人（会计主管人员）解中 超声明：保证半年度报告中财务报告的真实、准确、完整。 六、 董事会决议通过的本报告期利润分配预案或公积金转增股本预案 不适用 七、 是否存在公司治理特殊安排等重要事项 □适用 √不适用 八、 前瞻性陈述的风险声明 √适用 □不适用 本报告中涉及的未来计划、发展战略等前瞻性描述，不构成公司对投 ...

Core Viewpoint - The announcement highlights the successful completion of Phase Ia and Ib clinical trials for the innovative drug SGC001 injection by the affiliated company ShunJing Pharmaceutical, indicating promising results for acute myocardial infarction treatment [1] Group 1: Clinical Trial Results - SGC001 injection has completed Phase Ia clinical research in healthy volunteers and Phase Ib clinical observation in patients with ST-segment elevation myocardial infarction [1] - No grade 3 or higher adverse events were reported across all dosage groups, suggesting a favorable safety profile [1] - Preliminary efficacy results align with expectations, indicating potential effectiveness for acute myocardial infarction patients [1] Group 2: Market Context - There are currently no antibody drugs for acute myocardial infarction that have entered clinical research or approval stages, positioning SGC001 as a potentially pioneering treatment in this area [1]

证券代码：688068 证券简称：热景生物 公告编号：2025-059 北京热景生物技术股份有限公司 三、风险提示 舜景医药 SGC001 注射液当前已完成 Ib 期所有受试者的临床观察，并 已锁库、揭盲，目前正处于研究数据的统计分析阶段，Ib 期完整的有效性 和安全性等信息将在正式数据分析报告中呈现。舜景医药将按国家药品注 册的相关规定和要求开展后续临床研究工作。 关于参股公司 SGC001 创新药 I 期临床研究进展的 自愿披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 近日，北京热景生物技术股份有限公司（以下简称"公司"或"热景生物"） 收到参股公司北京舜景生物医药技术有限公司（以下简称"舜景医药"）关于自 主研制的创新药 SGC001 注射液 I 期临床研究进展的汇报：该项目目前已完成健 康志愿者 Ia 期的临床研究，前壁 ST 段抬高型心肌梗死患者的 Ib 期临床研究进 展顺利，完成了所有受试者的临床观察，并已锁库、揭盲。具体情况如下： 一、临床进展情况 舜景医药开展的创新药 SGC001 注射液分别在 ...

Core Viewpoint - The announcement from Hotgen Biotech (688068.SH) highlights the successful completion of clinical trials for its innovative drug SGC001, indicating potential for acute myocardial infarction treatment [1] Group 1: Clinical Trial Results - SGC001 injection has completed Phase Ia clinical research in healthy volunteers and Phase Ib clinical observation in patients with ST-segment elevation myocardial infarction [1] - No grade 3 or higher adverse events were reported across all dosage groups, and preliminary efficacy results align with expectations [1] - The drug is currently in the data statistical analysis phase, focusing on its application for emergency treatment of acute myocardial infarction patients [1] Group 2: Market Context - There are currently no antibody drugs for acute myocardial infarction (AMI) in clinical research or approved for market, positioning SGC001 as a potentially unique offering in this therapeutic area [1]

Core Viewpoint - The company has received an update on the progress of its innovative drug SGC001 injection from its associate Beijing ShunJing Biopharmaceutical Technology Co., Ltd, indicating positive advancements in clinical trials [1] Group 1: Clinical Research Progress - The SGC001 injection has completed Phase Ia clinical research with healthy volunteers [1] - The Phase Ib clinical research for patients with anterior ST-segment elevation myocardial infarction is progressing smoothly, with all subjects' clinical observations completed and data locked and unblinded [1] Group 2: Safety and Efficacy - SGC001 injection has shown good safety and tolerability in both healthy volunteers and patients with anterior ST-segment elevation myocardial infarction [1] - In the Phase Ib clinical study, no grade 3 or higher adverse events occurred across low (300 mg), medium (600 mg), and high (900 mg) dosage groups, and no serious adverse events were reported [1] - Preliminary analysis indicates that the initial efficacy results for SGC001 in patients with anterior ST-segment elevation myocardial infarction are generally in line with expectations, with statistical analysis and report summarization currently underway [1]

创新药概念股短线走弱，南新制药跌超12%，热景生物跌超9%，舒泰神、苑东生物、美迪西跟跌。 ...

Group 1 - The A-share chemical pharmaceutical sector experienced a sharp rise followed by a decline on August 28, with notable drops in stocks such as Nanxin Pharmaceutical and Rejing Bio, both falling over 10% [1] - Other companies in the sector, including Shutaishen, Yuandong Bio, Kanghong Pharmaceutical, and Kangyuan Pharmaceutical, also saw declines [1]

创新药概念股短线走弱，南新制药跌超10%，热景生物跌超8%，舒泰神、苑东生物、美迪西纷纷下 挫。 ...

Market Overview - The A-share market experienced a pullback in the afternoon, with the Shanghai Composite Index down 1.76%, the Shenzhen Component down 1.43%, and the ChiNext Index down 0.69% [1] - The total trading volume exceeded 3.19 trillion yuan, marking the third instance in A-share history to surpass 3 trillion yuan in a single day [1] Active Sectors - Rare earth permanent magnet stocks showed strong performance, with Beikong Technology hitting the daily limit and Northern Rare Earth rising over 8%, leading the hot stock list [3][4] - The computing power leasing concept also gained traction, with Hongjing Technology surging over 19% at one point, closing up 8.71% [3] Rare Earth Sector Drivers - Key drivers for the rare earth sector include: 1. Policy support from the Ministry of Industry and Information Technology, which recently issued regulations on rare earth mining and separation [3] 2. Significant revenue growth reported by Northern Rare Earth, with a 45.24% increase in revenue to 18.866 billion yuan and a staggering 1951.52% increase in net profit to 931 million yuan [3][4] 3. Continuous price increases for rare earth minerals and magnetic materials, maintaining a tight supply-demand balance [4] 4. Positive industry fundamentals, with robust demand from both upstream and downstream sectors [4] 5. Technological advancements by leading companies, enhancing competitiveness and reducing costs [4] Innovation Drug Sector - The innovation drug sector faced a downturn, with notable declines in stocks such as Yuekang Pharmaceutical down over 16% and Hejing Bio down over 10% [5] - Analysts suggest that as the mid-year report season concludes, market focus will shift towards new directions, particularly in innovation drugs and overseas expansion [6]

每经AI快讯，8月26日，创新药概念股表现低迷，广生堂、苑东生物、阳光诺和、海特生物、热景生 物、凯莱英、立方制药、济民健康等多股跌超5%。 （文章来源：每日经济新闻） ...